Vidhya Narendran

Vidhya Narendran currently serves as a Senior Business Development Executive at the Office of Industrial Consultancy and Sponsored Research at IIT Madras, where she plays a pivotal role in fostering industry-academia collaborations and advancing innovative technological solutions. Leveraging her multidisciplinary background as a chemist with over three years of experience spanning the pharmaceutical industry, regulatory affairs, and intellectual property rights (IP), Vidhya brings a comprehensive perspective to her role. Her expertise in technology transfer and licensing is instrumental in bridging the gap between cutting-edge research and commercial application. She actively manages invention disclosures (IDFs), conducts technology readiness assessments (TRL), and prepares compelling value propositions and technical flyers tailored for industry partners, including PCT filings, granted patents, and industry-specific tech meet presentations.

Vidhya’s proficiency in industry outreach is evident through her strategic engagement with senior management and key decision-makers in relevant companies, facilitating licensing opportunities and fostering long-term collaborations. She adeptly arranges meetings, drafts term sheets, and navigates patent technology classifications to streamline the commercialization process. Her skills in digital marketing, patent law, and regulatory compliance enable her to effectively communicate complex scientific concepts and ensure alignment with industry standards, including Medical Device Regulation (MDR) and pharmaceutical management protocols.

Her comprehensive understanding of clinical data, pharmaceutical chemistry, and laboratory skills complements her business development initiatives, making her a valuable asset in translating research innovations into market-ready solutions. Vidhya’s holistic approach, combining technical expertise with strategic industry engagement, positions her as a key driver in IIT Madras’s efforts to promote innovation, secure intellectual property rights, and accelerate technology commercialization in the biomedical and pharmaceutical sectors.